IP Library › Patent Application 12130903
Patent Application
App. No. 12/130,903

METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/130,903
Abstract

Administration of Oxybutynin in nebulized dry powder form directly to a patient's lungs for treating urinary incontinence or respiratory disease.

Claims (37)

1 . A method for treatment of urinary incontinence comprising delivering directly to a patient's lungs a systemically therapeutically effective amount of Oxybutynin in dry powder form.

2 . The method according to claim 1 , wherein the Oxybutynin comprises Oxybutynin Chloride.

3 . The method according to claim 1 , for treating symptoms of stress urinary incontinence.

4 . The method according to claim 1 , for treating symptoms of urge urinary incontinence.

5 . The method according to claim 1 , wherein the Oxybutynin is delivered using a dry powder inhaler (DPI).

6 . The method according to claim 1 , wherein the dry powder inhaler includes a piezo vibrator.

7 . The method according to claim 5 , wherein the dry powder Oxybutynin is delivered in dry powder form having a maximum powder size of 0.5-10 microns.

8 . The method according to claim 6 , wherein the dry powder Oxybutynin is delivered in dry powder form having a maximum particle size of 1-6 microns.

9 . The method according to claim 3 , wherein the therapeutically effective amount is within the range of 1 micron to 20 mg/kg per dose, administered as needed.

10 . The method according to claim 9 , wherein the therapeutically effective amount is within the range of 1 to 10 mg/kg per dose, administered as needed.

11 . The method according to claim 4 , wherein the therapeutically effective amount is within the range of 1 micron to 20 mg/day.

12 . The method according to claim 11 , wherein the therapeutically effective amount is within the range of 1 to 10 mg/day.

13 . Oxybutynin in dry powder form having a maximum particle size of 0.5-10 microns.

14 . Oxybutynin in dry powder form according to claim 13 , wherein the maximum particle size is 1-6 microns.

15 . Oxybutynin in dry powder form according to claim 13 , in dosage unit form.

16 . Oxybutynin in dry powder form according to claim 15 , wherein the dose comprises 1 micron to 20 mg/kg.

17 . Oxybutynin in dry powder form according to claim 15 , wherein the dose comprises 1 to 10 mg/kg.

18 . Oxybutynin in dry powder form according to claim 13 , in a dry powder inhaler (DPI).

19 . Oxybutynin in dry powder form according to claim 1 , wherein the dry powder inhaler includes a piezo vibrator.

20 . A method for administering Oxybutynin to a mammal suffering from incontinence to treat said incontinence, comprising the steps of:

providing a dry powder inhaler having a chamber containing Oxybutynin in dry powder form; and

coupling a vibrator to said chamber to generate a cloud of dry powder Oxybutynin for delivery to said mammal.

21 . A method for treatment of respiratory disease comprising delivering directly to a patient's lungs a systemically therapeutically effective amount of Oxybutynin in dry powder form.

22 . The method according to claim 21 , wherein the Oxybutynin comprises Oxybutynin Chloride.

23 . The method according to claim 21 , for treating symptoms of asthma.

24 . The method according to claim 21 , for treating symptoms of COPD.

25 . The method according to claim 21 , wherein the Oxybutynin is delivered using a dry powder inhaler (DPI).

26 . The method according to claim 21 , wherein the dry powder inhaler includes a piezo vibrator.

27 . The method according to claim 25 , wherein the dry powder Oxybutynin is delivered in dry powder form having a maximum powder size of 0.5-10 microns.

28 . The method according to claim 26 , wherein the dry powder Oxybutynin is delivered in dry powder form having a maximum particle size of 1-6 microns.

29 . The method according to claim 23 , wherein the therapeutically effective amount is within the range of 1 micron to 20 mg/kg per dose, administered as needed.

30 . The method according to claim 29 , wherein the therapeutically effective amount is within the range of 1 to 10 mg/kg per dose, administered as needed.

31 . The method according to claim 24 , wherein the therapeutically effective amount is within the range of 1 micron to 20 mg/day.

32 . The method according to claim 31 , wherein the therapeutically effective amount is within the range of 1 to 10 mg/day.

33 . A method for administering Oxybutynin to a mammal suffering from pulmonary disease to treat said disease, comprising the steps of:

providing a dry powder inhaler having a chamber containing Oxybutynin in dry powder form; and

coupling a vibrator to said chamber to generate a cloud of dry powder Oxybutynin for delivery to said mammal.

Assignments (2)
CHANGE OF NAME Recorded Apr 3, 2009
From: MICRODOSE TECHNOLOGIES, INC.
To: MICRODOSE THERAPEUTX, INC.
Reel/Frame 022494/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2008
From: MARTIN, MICHAEL J.
To: MICRODOSE TECHNOLOGIES, INC.
Reel/Frame 021141/0628 →